



6116105

1632/4

Express Mail No. ED 884 288 775 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: HARIRI, Robert J.

Confirmation No.: 1042

Serial No.: 10/074,976

Art Unit: 1632

Filed: February 13, 2002

Examiner: Li, Qian Janice

For: RENOVATION AND
REPOPULATION OF
DECELLULARIZED TISSUES
AND CADAVERIC ORGANS BY
STEM CELLS

Attorney Docket No.: 9516-101-999
(CAM:) (501872-999100)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:

1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.

1b. A legible copy of:

☒ Each publication or that portion which caused it to be listed on the PTO-1449;

☐ For each cited pending U.S. application filed before June 30, 2003, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;

☐ all other information or portion which caused it to be listed on the PTO-1449.

1c. ☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.

1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.

1e. ☐ Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. patents and U.S. patent application publications are not submitted herewith.

2. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):

06/17/2005 JBALINAN 00000116 503013 10074976

01 FC:1806

180.00 DA

- ☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
 - ☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - ☐ Before the mailing of the first Office action on the merits;
 - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

(Check either Item 3a or 3b)

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☒ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
- ☐ enclosed
 - ☒ to be charged to Jones Day Deposit Account No. 50-3013.

(Item 3b to be checked if any reference known for more than 3 months)

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The Certification Statement in Item 5 below is applicable.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- ☐ enclosed.
 - ☐ to be charged to Jones Day Deposit Account No. 50-3013
5. ☐ Certification Statement (applicable if Item 3a or Item 4 is checked)

(Check either Item 5a or 5b)

- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- 5b. ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 5c. ☐ Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
6. ☐ This application is a continuation application under 37 C.F.R. §1.53(b) or (d).

(Check appropriate Items 6a, 6b and/or 6c)

- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b. ☐ Copies of publications listed on Form PTO-1449 from prior application Serial No. _____, filed on _____, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. _____, filed on _____, and are provided herewith.
7. ☒ This is a Supplemental Information Disclosure Statement.
- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on _____. A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on _____.
8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

(Check Item 8a, 8b, or 8c)

- 8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b. ☐ set forth in the application.
- 8c. ☐ enclosed as an attachment hereto.
9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 50-3013.
10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Date: June 14, 2005

Respectfully submitted,

By: Anthony M. Insogna
Anthony M. Insogna


Reg. No.

49,020

35,203

(Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.
9516-101-999
(CAM: 501872-999100)

APPLICATION NO.
10/074,976

APPLICANT
HARIRI, Robert J.

CONFIRMATION NO.
1042

FILING DATE
February 13, 2002

GROUP
1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO 98/37903		PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Moore et al. "A simple perfusion technique for the isolation of maternal intervillous blood mononuclear cells from human placenta," <i>J. Immunological Meths.</i> 209(1):93-104 (1997)
	C02	Contractor, et al., "A comparison of the effects of different perfusion regimes on the structure of the isolated human placental lobule," <i>Cell and Tissue Res.</i> 237(3):609-617

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



First Legal Support Services

Los Angeles	(213) 250-1111	• Fax (213) 250-1197
Direct line to legal	(213) 250-9111	• Fax (213) 250-1197
Los Angeles (West)	(310) 277-9111	• Fax (310) 277-9153
Direct line to legal	(310) 277-7101	• Fax (310) 277-9153
Inland Empire	(909) 779-1110	• Fax (909) 779-0100
San Diego	(619) 231-9111	• Fax (619) 231-1361
San Francisco	(415) 626-3111	• Fax (415) 626-1331
Santa Ana	(714) 541-1110	• Fax (714) 541-8182
Sacramento	(619) 444-5111	• Fax (916) 443-3111

MESSENGER FORM FOR MESSENGER USE ONLY		DATE: 6/14/05	CTL #: 713940	
CHARGE TO: JONES DAY		AUTHORIZATION / REQUESTED BY		
EXPRESS MAIL NO.: ED 084 208 155 US		L. Graham		
4516-101-999		CHARGE REFERENCE		
		501872-999001		
PICK UP FROM: JONES DAY	DELIVER TO: THE U.S. POST OFFICE			
12750 High Bluff Drive, Suite 300 San Diego 92130	2535 Midway Drive San Diego 92110			
TO SEE: Kay or Jayne	TO SEE:			
PHONE: (858) 314-1141 OR (858) 314-1200	PHONE:			
<input type="checkbox"/> SPECIAL	<input type="checkbox"/> REGULAR (3 to 4 Hours)	<input type="checkbox"/> RETURN	Pieces	
<input type="checkbox"/> ASAP (1 Hour)	<input type="checkbox"/> NEXT DAY (By _____)	<input type="checkbox"/> NIGHT / WEEKEND SERVICE	Weight	
<input type="checkbox"/> RUSH (1 to 2 Hours)			P/U Time	
SPECIAL INSTRUCTIONS PLEASE DELIVER THIS/THESE ITEM(S) TO THE POST OFFICE TODAY. Express Mail Receipt must be date stamped with TODAY'S DATE. Please return the date-stamped receipt to us on the next business day. Thank you.				
LEGIBLE SIGNATURE	DEL TIME	DRIVER	CHECK NO.	AMOUNT
		1	1	1
		2	2	2

LIABILITY FOR LOSS OR DAMAGE TO ITEMS LIMITED TO \$250.00

MEMBER FIRM - CALIFORNIA ASSOCIATION OF PHOTOCOPIERS AND PROCESS SERVERS
NATIONAL ASSOCIATION OF PROFESSIONAL PROCESS SERVCSRS